Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
| ▸ | TUBB | P07437 | 1/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25273441 | 0.93 | LMNA (0.47) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL2798396 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL30780970 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL10983166 | 0.85 | LMNA (0.51) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL517768 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL29661436 | 0.85 | ALDH1A1 (0.50) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL11661312 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL31757016 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL30801468 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTTDP1KDM4ECYP3A4 | |
| SCHEMBL12458650 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPTTDP1KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081802-A | Heterocyclic substituted benzamide derivative and application thereof | 南华大学附属第一医院 | 2025-06-03 | — | — | CN | disclosed |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | INNOVATION INSTITUTE FOR ARTIFICIAL INTELLIGENCE IN MEDICINE OF ZHEJIANG UNIVERSITY (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4506343-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2025-02-12 | — | — | EP | disclosed |
| US-20240408216-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2024-12-12 | — | — | US | disclosed |
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | VORONOI INC. (KR) | 2024-11-21 | — | — | US | disclosed |
| CN-118946557-A | Heteroaryl derivatives and uses thereof | 株式会社沃若诺伊 | 2024-11-12 | — | — | CN | disclosed |
| EP-4361163-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2024-05-01 | — | — | EP | disclosed |
| US-20240091226-A1 | Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor | SUMITOMO PHARMA ONCOLOGY, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-117203216-A | Protein inhibitor or degradation agent, pharmaceutical composition containing same and medical application | 和径医药科技（上海）有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ALDH1A1 3986/4885MAPT 2274/4885TDP1 1830/4885 |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | ALDH1A1 3410/4885MAPT 2367/4885TDP1 1064/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | ALDH1A1 3410/4885MAPT 2367/4885TDP1 1064/4885 |
| US-20250101052-A1 | COMPOUND FOR EGFR KINASE INHIBITOR, COMPOSITION, AND USE THEREOF | EGFR, ERBB2, ERBB3 | ALDH1A1 2593/4885MAPT 2724/4885TDP1 4147/4885 |
| US-20240408216-A1 | PROTEIN INHIBITOR OR DEGRADING AGENT, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PHARMACEUTICAL USE | PSME1, IDE, PRUNE1 | ALDH1A1 4213/4885MAPT 388/4885TDP1 2032/4885 |
| US-20240091226-A1 | Forms and Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor | TNK1, TNNI3K, TYK2 | ALDH1A1 4034/4885MAPT 522/4885TDP1 596/4885 |
| US-20240383923-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | ERBB2, ERBB3, EGFR | ALDH1A1 955/4885MAPT 2826/4885TDP1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.